LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

4.09 -3.76

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.91

Max

4.37

Galvenie mērījumi
By Trading Economics
Ienākumi	-8.5M -35M
Darbinieki	106
EBITDA	-11M -37M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+63.55% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 19. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	131M 295M
Iepriekšējā atvēršanas cena	7.85
Iepriekšējā slēgšanas cena	4.09

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. maijs 22:54 UTC

Peļņas

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026. g. 13. maijs 23:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. maijs 23:51 UTC

Tirgus saruna

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026. g. 13. maijs 23:45 UTC

Tirgus saruna

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026. g. 13. maijs 23:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 13. maijs 23:17 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 13. maijs 23:16 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026. g. 13. maijs 23:15 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026. g. 13. maijs 23:14 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026. g. 13. maijs 23:02 UTC

Tirgus saruna

Peļņas

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026. g. 13. maijs 22:59 UTC

Tirgus saruna

Peļņas

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026. g. 13. maijs 22:24 UTC

Peļņas

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026. g. 13. maijs 22:23 UTC

Peļņas

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026. g. 13. maijs 22:23 UTC

Peļņas

Xero FY International Revenue Growth 47%>XRO.AU

2026. g. 13. maijs 22:22 UTC

Peļņas

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026. g. 13. maijs 22:19 UTC

Peļņas

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026. g. 13. maijs 22:19 UTC

Peļņas

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026. g. 13. maijs 22:18 UTC

Peļņas

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026. g. 13. maijs 22:16 UTC

Peļņas

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026. g. 13. maijs 22:15 UTC

Peļņas

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026. g. 13. maijs 22:15 UTC

Peļņas

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026. g. 13. maijs 22:13 UTC

Peļņas

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026. g. 13. maijs 22:12 UTC

Peļņas

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026. g. 13. maijs 22:11 UTC

Peļņas

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026. g. 13. maijs 22:11 UTC

Peļņas

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026. g. 13. maijs 22:10 UTC

Peļņas

Xero Did Not Declare a Dividend>XRO.AU

2026. g. 13. maijs 22:10 UTC

Peļņas

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026. g. 13. maijs 22:09 UTC

Peļņas

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026. g. 13. maijs 22:00 UTC

Peļņas

Cisco to Shed Jobs for All-In AI Push -- Update

2026. g. 13. maijs 21:11 UTC

Peļņas

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

63.55% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 63.55%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.